CSPC PHARMACEUT.GR. ADR4 Working Capital to Net Assets Ratio
CSPC PHARMACEUT.GR. ADR4 working capital to net assets ratio. CSPC PHARMACEUT.GR. ADR4 (CVGU) has a Working Capital to Net Assets ratio of 41.7% as of June 2026. Working capital of €16.43 Billion (current assets of €30.86 Billion minus current liabilities of €14.42 Billion) is measured against net assets of €39.43 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check CSPC PHARMACEUT.GR. ADR4 tangible book value ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of CSPC PHARMACEUT.GR. ADR4 (2021–2025)
Working capital to net assets ratio of CSPC PHARMACEUT.GR. ADR4 from 2021 to 2025. This chart shows how CSPC PHARMACEUT.GR. ADR4's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of June 2026, the ratio stands at 41.7%, reflecting working capital of €16.43 Billion against net assets of €39.43 Billion EUR. See CVGU days of operational coverage to measure how many days the company can operate on defensive assets alone.
CSPC PHARMACEUT.GR. ADR4 Working Capital to Net Assets Ratio by Year (2021–2025)
CSPC PHARMACEUT.GR. ADR4 working capital to net assets ratio by year from 2021 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for CSPC PHARMACEUT.GR. ADR4 from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of CSPC PHARMACEUT.GR. ADR4.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 34.9% | €12.07 Billion | €34.55 Billion | €22.25 Billion | €10.18 Billion | ▼ -1.2 pp |
| 2024 | 36.2% | €12.25 Billion | €33.87 Billion | €21.89 Billion | €9.63 Billion | ▼ -11.1 pp |
| 2023 | 47.3% | €16.56 Billion | €35.02 Billion | €26.74 Billion | €10.18 Billion | ▼ -0.1 pp |
| 2022 | 47.4% | €15.00 Billion | €31.64 Billion | €23.96 Billion | €8.96 Billion | ▼ -1.5 pp |
| 2021 | 48.9% | €13.11 Billion | €26.83 Billion | €20.34 Billion | €7.23 Billion | — |